1239596-53-2

Usage

Uses

Used in Pharmaceutical Research and Development:
1-benzyl-3,3-difluoropiperidin-4-ol is utilized as a key intermediate in the synthesis of new medications, leveraging its unique structural features to contribute to the development of novel therapeutic agents. Its presence in the molecular composition of potential drug candidates is attributed to its ability to enhance biological activities and improve the pharmacological profile of medications.
Used in Organic Synthesis:
In the realm of organic synthesis, 1-benzyl-3,3-difluoropiperidin-4-ol serves as a versatile building block, enabling the creation of a diverse array of chemical compounds. Its structural attributes, including the benzyl group and fluorine atoms, facilitate its integration into complex organic molecules, thereby expanding the scope of chemical reactions and the synthesis of new compounds with potential applications across various industries.
Used in Medicinal Chemistry:
1-benzyl-3,3-difluoropiperidin-4-ol is employed as a subject of study in medicinal chemistry, where its properties and potential uses are explored to understand its role in the development of pharmaceuticals. Researchers investigate its interactions with biological targets and its capacity to modulate biological pathways, which can inform the design of new drugs with improved efficacy and safety profiles.

Upstream product

• 1067914-81-1 3,3-difluoro-1-(phenylmethyl)-4,4-piperidinediol 
• 23583-21-3 ethyl-3-benzylamino propionate 
• 851314-56-2 ethyl 5,5-difluoro-4-hydroxy-1-(phenylmethyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate 

Downstream Products

• 1239596-54-3 3,3-difluoropiperidin-4-ol 
• 1820679-70-6 (±)-tert-butyl 4-amino-3,3-difluoropiperidine-1-carboxylate 
• 1067914-82-2 (±)-tert-butyl 4-(benzylamino)-3,3-difluoropiperidine-1-carboxylate 
• 1334412-95-1 tert-butyl 4-(2-ethoxy-2-oxoethyl)-3,3-difluoropiperidine-1-carboxylate 
• 1215071-17-2 tert-butyl 3,3-difluoro-4-oxo-piperidine-1-carboxylate 
• 1209780-71-1 tert-butyl 3,3-difluoro-4-hydroxy-piperidine-1-carboxylate 

Relevant academic research and scientific papers

5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUND CAPABLE OF PASSING THROUGH BLOOD-BRAIN BARRIER

The present invention discloses 5-substituted difluoropiperidine compounds having a capacity to cross the blood-brain barrier; the compound has the structural formula represented by formula (I): The 5-substituted difluoropiperidine compounds, derivatives

SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY

The present invention discloses substituted quinazoline compounds having a capacity to cross the blood-brain barrier; the compound has the structural formula represented by formula (I): The quinazoline compounds, derivatives and pharmaceutically acceptabl

Quinazoline derivative salt-type crystal forms and preparation method and application thereof

The invention discloses quinazoline derivative salt-type crystal forms and a preparation method and application thereof. The quinazoline derivative salt-type crystal forms are specifically the hydrochloride crystal forms A, B, C, D, F, H, I, the sulphate

PIPERIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

Bridged Spiro[2.4]heptane Ester Derivatives

The invention relates to a method for preparing linear polymers having an amide end or having a star architecture comprising an amide core, by means of a ring opening using lactide and glycolide monomers or a lactide monomer ring in the presence of a cata

FLUORINATED BRIDGED SPIRO[2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AGONISTS

The present invention relates to fluorinated bridged spiro[2.4]heptane derivatives of formula (I), wherein n and R1 are as defined in the description, their preparation and their pharmaceutically active compounds.

BRIDGED SPIRO[2.4]HEPTANE ESTER DERIVATIVES

The present invention relates to bridged spiro[2.4]heptane ester derivatives of formula (I) wherein W, Y, R1 and R2 are as defined in the description, their preparation and their use as pharmaceutically active compounds.

PROTEIN KINASE C INHIBITORS AND USES THEREOF

This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.